Seres Therapeutics Ownership | Who Owns Seres Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Seres Therapeutics Ownership Summary


Seres Therapeutics is owned by 41.53% institutional investors, 13.19% insiders, and 45.28% retail investors. Flagship pioneering is the largest institutional shareholder, holding 15.82% of MCRB shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 5.58% of its assets in Seres Therapeutics shares.

MCRB Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSeres Therapeutics41.53%13.19%45.28%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Flagship pioneering23.12M15.82%$16.73M
Fmr22.72M15.55%$16.44M
Vanguard group6.29M4.30%$4.55M
Tang capital management2.41M1.65%$1.74M
Millennium management1.78M1.22%$1.29M
Blackrock1.76M1.21%$1.28M
Geode capital management1.13M0.78%$820.70K
Northern trust721.76K0.49%$522.41K
Jane street group707.07K0.48%$511.78K
Goldman sachs group666.95K0.46%$482.74K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Flagship pioneering23.12M1.98%$16.73M
Lion point capital, lp340.76K0.45%$246.64K
Tang capital management2.41M0.18%$1.74M
Providence wealth advisors76.25K0.05%$57.95K
Point72 asia (singapore) pte.127.63K0.02%$92.38K
Harbourvest partners49.36K0.02%$35.73K
Ironwood investment management43.30K0.02%$31.34K
Auour investments17.00K0.00%$12.30K
Aries wealth management17.00K0.00%$12.30K
Point72 (difc)87.75K0.00%$63.52K

Top Buyers

HolderShares% AssetsChange
Tang capital management2.41M0.18%1.50M
Millennium management1.78M0.00%750.05K
Jane street group707.07K0.00%620.63K
Point72 asia (singapore) pte.127.63K0.02%127.63K
Ubs group200.73K-94.76K

Top Sellers

HolderShares% AssetsChange
Blackrock1.76M--5.06M
Woodline partners lp---2.05M
State street339.55K--1.61M
Bank of america corp /de/105.04K--1.55M
Handelsbanken fonder ab---1.10M

New Positions

HolderShares% AssetsChangeValue
Point72 (difc)87.75K0.00%87.75K$63.52K
Schonfeld strategic advisors60.10K0.00%60.10K$43.50K
Vanguard personalized indexing management26.52K0.00%26.52K$19.20K
Avantax advisory services16.68K0.00%16.68K$12.07K
Macquarie group4.95K-4.95K$3.58K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-20.00
Newedge advisors-200.00
Huntington national bank-230.00
Kelly financial services-240.00
New york state common retirement fund-791.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202481-14.74%63,396,268-8.26%411.86%27-41.30%26-3.70%
Jun 30, 202495-5.94%69,106,531-19.34%471.06%46-2.13%27-3.57%
Mar 31, 2024101-9.82%85,680,215-4.29%661.37%476.82%28-33.33%
Dec 31, 2023112-23.81%89,517,414-16.63%690.99%44-40.54%4231.25%
Sep 30, 2023147-2.65%107,377,449-4.75%841.05%74-22.92%3223.08%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S9.50M5.58%58.60K
Fidelity Growth Compy Commingled Pl O9.44M5.55%92.60K
Fidelity Growth Company Fund6.89M4.05%-14.63K
Vanguard Total Stock Mkt Idx Inv4.04M2.37%-
Fidelity Growth Company K62.55M1.50%-43.97K
Fidelity Series Growth Company1.87M1.10%-
Vanguard Institutional Extnd Mkt Idx Tr1.45M0.85%-
Vanguard Explorer Inv1.22M0.72%-
Fidelity Select Biotechnology854.35K0.50%-
Fidelity Extended Market Index739.10K0.43%72.60K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 18, 2024DesRosier Thomas Chief Legal Officer and EVPSell$474.73
Nov 18, 2024von Moltke Lisa See RemarksSell$528.26
Nov 18, 2024Young Teresa L. See RemarksSell$397.64
Nov 18, 2024Shaff Eric D. CEO and PresidentSell$1.35K
Nov 18, 2024Henn Matthew R. See RemarksSell$501.23

Insider Transactions Trends


DateBuySell
2024 Q4-10
2024 Q3-7
2024 Q2-6
2024 Q1-7
2023 Q4-8

MCRB Ownership FAQ


Who Owns Seres Therapeutics?

Seres Therapeutics shareholders are primarily institutional investors at 41.53%, followed by 13.19% insiders and 45.28% retail investors. The average institutional ownership in Seres Therapeutics's industry, Biotech Stocks , is 47.04%, which Seres Therapeutics falls below.

Who owns the most shares of Seres Therapeutics?

Seres Therapeutics’s largest shareholders are Flagship pioneering (23.12M shares, 15.82%), Fmr (22.72M shares, 15.55%), and Vanguard group (6.29M shares, 4.30%). Together, they hold 35.67% of Seres Therapeutics’s total shares outstanding.

Does Blackrock own Seres Therapeutics?

Yes, BlackRock owns 1.21% of Seres Therapeutics, totaling 1.76M shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.28M$. In the last quarter, BlackRock decreased its holdings by -5.063M shares, a -74.18% change.

Who is Seres Therapeutics’s biggest shareholder by percentage of total assets invested?

Flagship pioneering is Seres Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.98% of its assets in 23.12M Seres Therapeutics shares, valued at 16.73M$.

Who is the top mutual fund holder of Seres Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Seres Therapeutics shares, with 5.58% of its total shares outstanding invested in 9.5M Seres Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools